{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:23:45Z","timestamp":1773458625367,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.imlet.2016.05.002","type":"journal-article","created":{"date-parts":[[2016,5,10]],"date-time":"2016-05-10T14:33:49Z","timestamp":1462890829000},"page":"44-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Serum and tissue profile of VEGF and its receptors VGFR1\/R2 in children with infantile hemangiomas on systemic propranolol treatment"],"prefix":"10.1016","volume":"175","author":[{"given":"Przemyslaw","family":"Przewratil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f3zef","family":"Kobos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneta","family":"Wn\u0119k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Szemraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dariusz","family":"Wyrzykowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Chrzanowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Andrzejewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Taran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2016.05.002_bib0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-8722-7-13","article-title":"Signaling pathways in the development of infantile hemangioma","volume":"31","author":"Ji","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.imlet.2016.05.002_bib0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/bjd.12435","article-title":"Pathogenesis of infantile haemangioma","volume":"169","author":"Greenberger","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.imlet.2016.05.002_bib0015","first-page":"149","article-title":"The HIF-2alpha\/VEGF pathway activation in cutaneous capillary haemangiomas","volume":"37","author":"Giatromanolaki","year":"2005","journal-title":"Pathol. (Phila.)"},{"key":"10.1016\/j.imlet.2016.05.002_bib0020","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2016.05.002_bib0025","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa1404710","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma","volume":"372","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2016.05.002_bib0030","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00431-015-2570-0","article-title":"Treatment of infantile haemangiomas: recommendations of a European expert group","volume":"174","author":"Hoeger","year":"2015","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.imlet.2016.05.002_bib0035","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1111\/pde.12627","article-title":"Propranolol in the treatment of infantile hemangiomas: a meta-analysis in Chinese patients","volume":"32","author":"Li","year":"2015","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.imlet.2016.05.002_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1747-1028-8-1","article-title":"The role of \u03b2-adrenergic receptor signaling in the proliferation of hemangioma-derived endothelial cells","volume":"8","author":"Ji","year":"2013","journal-title":"Cell Div."},{"key":"10.1016\/j.imlet.2016.05.002_bib0045","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/SLA.0b013e318254ce7a","article-title":"Propranolol induces regression of hemangioma cells through HIF-1\u03b1-mediated inhibition of VEGF-A","volume":"256","author":"Chim","year":"2012","journal-title":"Ann. Surg."},{"key":"10.1016\/j.imlet.2016.05.002_bib0050","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.jpedsurg.2012.09.008","article-title":"Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells","volume":"47","author":"Ji","year":"2012","journal-title":"J. Pediatr. Surg."},{"key":"10.1016\/j.imlet.2016.05.002_bib0055","first-page":"48","article-title":"Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell","volume":"7","author":"Zhang","year":"2013","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.imlet.2016.05.002_bib0060","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2133.2010.09848.x","article-title":"Propranolol for infantile hemangiomas: insights into the molecular mechanisms of action","volume":"163","author":"Storch","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.imlet.2016.05.002_bib0065","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/pbc.25453","article-title":"Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K\/Akt\/eNOS\/VEGF pathway","volume":"62","author":"Pan","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.imlet.2016.05.002_bib0070","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.vph.2010.08.002","article-title":"B\u00e9liveau R.Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells","volume":"53","author":"Lamy","year":"2010","journal-title":"Vascul. Pharmacol."},{"key":"10.1016\/j.imlet.2016.05.002_bib0075","doi-asserted-by":"crossref","first-page":"e979699","DOI":"10.4161\/19381980.2014.979699","article-title":"Mechanisms of propranolol action in infantile hemangioma","volume":"6","author":"Kum","year":"2015","journal-title":"Dermatoendocrinology"},{"key":"10.1016\/j.imlet.2016.05.002_bib0080","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bjd.12592","article-title":"Upregulated autocrine vascular endothelial growth factor (VEGF)\/VEGF receptor-2 loop prevents apoptosis in haemangioma-derived endothelial cells","volume":"170","author":"Ji","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.imlet.2016.05.002_bib0085","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/labinvest.2012.175","article-title":"\u03b2-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines","volume":"93","author":"Moretti","year":"2013","journal-title":"Lab. Invest."},{"key":"10.1016\/j.imlet.2016.05.002_bib0090","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3892\/etm.2013.1159","article-title":"Induction of apoptosis in infantile hemangioma endothelial cells by propranolol","volume":"6","author":"Tu","year":"2013","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.imlet.2016.05.002_bib0095","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/pde.12192","article-title":"Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapy","volume":"30","author":"Chen","year":"2013","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.imlet.2016.05.002_bib0100","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.bjoms.2012.12.003","article-title":"Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients","volume":"51","author":"Yuan","year":"2013","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.imlet.2016.05.002_bib0105","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1097\/SLA.0000000000000450","article-title":"Propranolol: a novel antihemangioma agent with multiple potential mechanisms of action","volume":"261","author":"Ji","year":"2015","journal-title":"Ann. Surg."},{"key":"10.1016\/j.imlet.2016.05.002_bib0110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cyto.2009.11.012","article-title":"Local serum levels of vascular endothelial growth factor in infantile hemangioma: intriguing mechanism of endothelial growth","volume":"49","author":"Przewratil","year":"2010","journal-title":"Cytokine"},{"key":"10.1016\/j.imlet.2016.05.002_bib0115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/01.PRS.0000170804.80834.5F","article-title":"Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients","volume":"116","author":"Zhang","year":"2005","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.imlet.2016.05.002_bib0120","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.4081\/ejh.2014.2263","article-title":"Knockdown of VEGFR2 inhibits proliferation and induces apoptosis in hemangioma-derived endothelial cells","volume":"58","author":"Ou","year":"2014","journal-title":"Eur. J. Histochem."},{"key":"10.1016\/j.imlet.2016.05.002_bib0125","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3892\/etm.2012.654","article-title":"Propranolol treatment of infantile hemangioma endothelial cells: a molecular analysis","volume":"4","author":"Stiles","year":"2012","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.imlet.2016.05.002_bib0130","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1038\/bjc.2013.205","article-title":"\u03b2-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma","volume":"108","author":"Pasquier","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.imlet.2016.05.002_bib0135","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nrclinonc.2011.123","article-title":"Targeted therapies: using \u03b2-blockers to inhibit breast cancer progression","volume":"8","author":"Powe","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247816300700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247816300700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T09:54:54Z","timestamp":1567850094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247816300700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":27,"alternative-id":["S0165247816300700"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2016.05.002","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum and tissue profile of VEGF and its receptors VGFR1\/R2 in children with infantile hemangiomas on systemic propranolol treatment","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2016.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}